Pubfacts - Scientific Publication Data
  • Categories
  • Journals
  • ->
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia.

Authors:
Marco Benkisser-Petersen Maike Buchner Arlette Dörffel Marcus Dühren-von-Minden Rainer Claus Kathrin Kläsener Kerstin Leberecht Meike Burger Christine Dierks Hassan Jumaa Fabio Malavasi Michael Reth Hendrik Veelken Justus Duyster Katja Zirlik

PLoS One 2016 30;11(12):e0169159. Epub 2016 Dec 30.

Department of Hematology, Oncology and Stem cell transplantation, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

The survival and proliferation of CLL cells depends on microenvironmental contacts in lymphoid organs. CD38 is a cell surface receptor that plays an important role in survival and proliferation signaling in CLL. In this study we demonstrate SYK's direct involvement in the CD38 signaling pathway in primary CLL samples. CD38 stimulation of CLL cells revealed SYK activation. SYK downstream target AKT was subsequently induced and MCL-1 expression was increased. Concomitant inhibition of SYK by the SYK inhibitor R406 resulted in reduced activation of AKT and prevented upregulation of MCL-1. Moreover, short-term CD38 stimulation enhanced BCR-signaling, as indicated by increased ERK phosphorylation. CXCL12-dependent migration was increased after CD38 stimulation. Treating CLL cells with R406 inhibited CD38-mediated migration. In addition, we observed marked downregulation of CD38 expression for CLL cells treated with R406 compared to vehicle control. Finally, we observed a clear correlation between CD38 expression on CLL cells and SYK-inhibitor efficacy. In conclusion, our study provides deeper mechanistic insight into the effect of SYK inhibition in CLL.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0169159PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5201248PMC
July 2017

Publication Analysis

Top Keywords

cll cells
20
cd38 stimulation
12
cd38
8
cd38 expression
8
expression cll
8
cll
8
survival proliferation
8
syk
5
cells
5
increased cd38
4
cells r406
4
revealed syk
4
syk activation
4
downstream target
4
activation syk
4
syk downstream
4
stimulation treating
4
treating cll
4
stimulation cll
4
migration addition
4

Altmetric Statistics


Show full details
5 Total Shares
4 Tweets
5 Citations

Similar Publications

Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia.

Authors:
Miguel Quijada-Álamo Claudia Pérez-Carretero María Hernández-Sánchez Ana-Eugenia Rodríguez-Vicente Ana-Belén Herrero Jesús-María Hernández-Sánchez Marta Martín-Izquierdo Sandra Santos-Mínguez Mónica Del Rey Teresa González Araceli Rubio-Martínez Alfonso García de Coca Julio Dávila-Valls José-Ángel Hernández-Rivas Helen Parker Jonathan C Strefford Rocío Benito José-Luis Ordóñez Jesús-María Hernández-Rivas

Clin Transl Med 2021 Feb;11(2):e304

Cancer Research Center, University of Salamanca, IBSAL, IBMCC, CSIC, Salamanca, Spain.

Background: Several genetic alterations have been identified as driver events in chronic lymphocytic leukemia (CLL) pathogenesis and oncogenic evolution. Concurrent driver alterations usually coexist within the same tumoral clone, but how the cooperation of multiple genomic abnormalities contributes to disease progression remains poorly understood. Specifically, the biological and clinical consequences of concurrent high-risk alterations such as del(11q)/ATM-mutations and del(17p)/TP53-mutations have not been established. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia.

Authors:
Damian Kovalovsky Jeong Heon Yoon Matthew G Cyr Samantha Simon Elisaveta Voynova Christoph Rader Adrian Wiestner Julie Alejo Stefania Pittaluga Ronald E Gress

Leukemia 2021 Feb 25. Epub 2021 Feb 25.

Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.

The only current curative treatment for chronic lymphocytic leukemia (CLL) is allogenic hematopoietic stem cell transplantation. Chimeric antigen receptor treatment targeting CD19 for CLL achieved some complete responses, suggesting the need for alternative or combinational therapies to achieve a more robust response. In this work, we evaluated CAR-T cells specific for Siglec-6, an antigen expressed in CLL, as a novel CAR-T cell treatment for CLL. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.

Authors:
Timothy L Chen Bonnie Harrington Jean Truxall Ronni Wasmuth Alexander Prouty Shelby Sloan Amy M Lehman Deepa Sampath Eric Orlemans Robert A Baiocchi Lapo Alinari John C Byrd Jennifer A Woyach Erin Hertlein

J Hematol Oncol 2021 Feb 24;14(1):36. Epub 2021 Feb 24.

Division of Hematology, Department of Internal Medicine, The Ohio State University, 462 OSUCCC, 410 W 12th Avenue, Columbus, OH, 43210, USA.

B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. However patients do still relapse on ibrutinib, and the progressive disease is often quite aggressive requiring immediate treatment. Several strategies are being pursued to treat patients who relapse on ibrutinib therapy. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

IL-17 and IL-23 levels in patients with early-stage chronic lymphocytic leukemia.

Authors:
Mehmet Bankir Didar Yanardag Acik

North Clin Istanb 2021 20;8(1):24-30. Epub 2020 Nov 20.

Department of Internal Medicine and Haematology, Adana City Training and Research Hospital, Adana, Turkey.

Objective: Cytokines produced by bone marrow mesenchymal stem cells are important components of the tumor microenvironment in chronic lymphocytic leukemia (CLL). The roles of IL-17 and IL-23 in both autoimmune diseases and tumor growth have been demonstrated. The role of the IL-17/23 axis in apoptosis has also been demonstrated in studies. Read More

View Article and Full-Text PDF
November 2020
Similar Publications

IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK.

Authors:
Rossana Maffei Stefania Fiorcari Stefania Benatti Claudio Giacinto Atene Silvia Martinelli Patrizia Zucchini Leonardo Potenza Mario Luppi Roberto Marasca

Leukemia 2021 Feb 23. Epub 2021 Feb 23.

Hematology Unit, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.

Interferon regulatory factor 4 (IRF4) is a transcriptional regulator of immune system development and function. Here, we investigated the role of IRF4 in controlling responsiveness to B-cell receptor (BCR) stimulation in chronic lymphocytic leukemia (CLL). We modulated IRF4 levels by transfecting CLL cells with an IRF4 vector or by silencing using small-interfering RNAs. Read More

View Article and Full-Text PDF
February 2021
Similar Publications
Save 15% Survey
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap